Fate Therapeutics Inc. (NASDAQ:FATE) shares traded down 1.7% during trading on Tuesday . The stock traded as low as $2.80 and last traded at $2.84, with a volume of 68,921 shares traded. The stock had previously closed at $2.89.

Several research analysts have commented on the company. BMO Capital Markets set a $4.00 target price on Fate Therapeutics and gave the stock a “buy” rating in a report on Monday, August 8th. Wells Fargo & Co. reissued a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday, May 10th. Zacks Investment Research raised Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a research note on Thursday, August 11th. Leerink Swann reissued an “outperform” rating and issued a $4.00 price objective on shares of Fate Therapeutics in a research note on Tuesday, June 21st. Finally, HC Wainwright initiated coverage on Fate Therapeutics in a research note on Thursday, July 28th. They issued a “buy” rating and a $9.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $6.29.

The stock’s market cap is $82.06 million. The firm has a 50-day moving average price of $2.11 and a 200-day moving average price of $1.88.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.03. The firm earned $1.03 million during the quarter, compared to the consensus estimate of $1.02 million. On average, analysts anticipate that Fate Therapeutics Inc. will post ($1.12) earnings per share for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.